<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133793</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00140741</org_study_id>
    <nct_id>NCT03133793</nct_id>
  </id_info>
  <brief_title>CoQ10 and D-ribose in Patients With Diastolic Heart Failure</brief_title>
  <official_title>Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by
      patients who have diastolic heart failure, or heart failure with preserved ejection fraction
      (HFpEF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in health status of patients with HFpEF</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Patients' perceptions of their symptoms will be measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a self-administered questionnaire that measures patients' perceptions of five domains of their health status relevant to HFpEF. The KCCQ is a 24 item questionnaire. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vigor</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Change will be measured using the the Vigor subscale from the Profile of Mood States (POMS) questionnaire.The subscale has 8 questions. Scores for the subscale range from 0-32, in which higher scores reflect more vigor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular diastolic function</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Change will be measured using advanced echocardiographic imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk test (6MWT)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>The 6-minute walking test (6MWT) is a simple test. Test measures the total distance in meters a person can walk in 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in venous blood B-type natriuretic peptide (BNP) levels</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>BNP concentration will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lactate/adenosine triphosphate (ATP) ratio</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>The lactate/ATP ratio will be measured for each participant.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>Placebo Only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will receive placebo pills and placebo powder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoQ10 Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive CoQ10 pills and placebo powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-ribose Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive placebo pills and D-ribose oral powder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoQ10 + D-ribose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive CoQ10 pills and D-ribose oral powder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CoQ10</intervention_name>
    <description>Participants will take 300mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.</description>
    <arm_group_label>CoQ10 Only</arm_group_label>
    <arm_group_label>CoQ10 + D-ribose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-Ribose Oral Powder</intervention_name>
    <description>Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.</description>
    <arm_group_label>D-ribose Only</arm_group_label>
    <arm_group_label>CoQ10 + D-ribose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo pills</intervention_name>
    <description>Participants will take matched placebo pills that are 300mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.</description>
    <arm_group_label>Placebo Only</arm_group_label>
    <arm_group_label>D-ribose Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo powder</intervention_name>
    <description>Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.</description>
    <arm_group_label>Placebo Only</arm_group_label>
    <arm_group_label>CoQ10 Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with HFpEF within a 6-month period

          -  New York Heart Association (NYHA) Classification II-III HF

          -  Have left ventricular ejection fraction (EF) â‰¥ 50% documented by an echocardiogram

          -  Have a telephone or reliable phone contact

          -  Have their own means of transportation to the study site

        Exclusion Criteria:

          -  Acute coronary syndrome in the past 12 weeks

          -  Significant valvular heart disease

          -  Severe cardiac fibrosis (galectin-3 level &gt; 26 ng/ml)

          -  Constrictive pericardium

          -  Pulmonary fibrosis

          -  Congenital heart disease

          -  Hypertrophic or infiltrative cardiomyopathy

          -  Heart transplant

          -  Left ventricular assist device

          -  Heart failure (HF) associated hospital admission or emergency room visit within past
             30 days

          -  Recent percutaneous coronary intervention

          -  Significant renal and/or hepatic dysfunction

          -  Severe cognitive impairment

          -  Consumption of any CoQ10 (ubiquinol) or D-ribose supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Pierce, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Thimmesch</last_name>
    <phone>(913) 588-4336</phone>
    <email>athimmesch@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure with preserved ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

